REG - BioPharma Credit PLC - Result of AGM

Biopharma CreditAnnouncement

09/06/2025 16:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250609:nRSI0669Ma&default-theme=true

RNS Number : 0669M  BioPharma Credit PLC  09 June 2025

BIOPHARMA CREDIT PLC

 

(THE "COMPANY")

 

 

RESULT OF 2025 ANNUAL GENERAL MEETING

 

The Company is pleased to announce that, at the Annual General Meeting held
today, all resolutions put to the meeting were passed by way of a poll.

 

 

 

 Resolutions                                                                  Votes        %        Votes Against  %      Total Votes  % of Total Voting Rights Voted  Votes Withheld(1)

                                                                              For
 1: To approve the continuation resolution                                    570,318,209  99.44%   3,188,644      0.56%  573,506,853  50.78%                          10,524,548
 2: To receive and accept the annual report and financial statements          565,083,635  100.00%  5,172          0.00%  565,088,807  50.04%                          18,942,594
 3: To approve the Directors' Remuneration Report                             579,743,647  99.96%   225,063        0.04%  579,968,710  51.36%                          4,062,691
 4: To re-elect Harry Hyman as a Director                                     501,932,822  96.85%   16,347,475     3.15%  518,280,297  45.89%                          65,751,104
 5: To re-elect Colin Bond as a Director                                      574,657,924  99.07%   5,390,941      0.93%  580,048,865  51.36%                          3,982,536
 6: To re-elect Duncan Budge as a Director                                    580,031,390  100.00%  17,475         0.00%  580,048,865  51.36%                          3,982,536
 7: To re-elect Stephanie Léouzon as a Director                               580,037,743  100.00%  11,122         0.00%  580,048,865  51.36%                          3,982,536
 8: To re-elect Sapna Shah as a Director                                      580,037,743  100.00%  11,122         0.00%  580,048,865  51.36%                          3,982,536
 9: To re-elect Rolf Soderstrom as a Director                                 580,037,743  100.00%  11,122         0.00%  580,048,865  51.36%                          3,982,536
 10: To re-appoint Ernst & Young LLP as Auditor to the Company                579,899,832  99.97%   196,131        0.03%  580,095,963  51.37%                          3,935,438
 11: To authorise the Directors to determine the remuneration of the Auditor  580,008,675  100.00%  21,228         0.00%  580,029,903  51.36%                          4,001,498
 12: To approve the Company's dividend payment policy                         580,095,804  100.00%  239            0.00%  580,096,043  51.37%                          3,935,358
 13: To authorise the allotment of shares by the Company                      579,965,234  99.98%   136,051        0.02%  580,101,285  51.37%                          3,930,116
 14: To authorise the disapplication of pre-emption rights                    579,892,518  99.97%   169,790        0.03%  580,062,308  51.36%                          3,969,093
 15: To authorise the Company to make market purchases                        580,088,531  100.00%  13,932         0.00%  580,102,463  51.37%                          3,928,938

 of ordinary shares
 16: To authorise the Company to hold general meetings                        580,056,976  99.99%   38,281         0.01%  580,095,257  51.37%                          3,936,144

 on 14 clear days' notice

 

1.     A 'vote withheld' is not a vote under English law and is not
counted in the calculation of votes 'for' or 'against' a resolution.

 

Copies of resolutions 13 to 16 have been submitted to the National Storage
Mechanism and will shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

 

9 June 2025

 

 

Enquiries:

 

BioPharma Credit plc

 

via MUFG Corporate Governance Limited

 

Company Secretary

 

+44 (0) 333 300 1932

 

Burson Buchanan

 

Mark Court / Jamie Hooper / Henry Wilson / Nick Croysdill

 

+44 (0)20 7466 5000

 

biopharmacredit@buchanan.uk.com (mailto:biopharmacredit@buchanan.uk.com)

 

 

 

Notes to Editors:

 

BioPharma Credit PLC is London's only listed specialist investor in debt from
the life sciences industry and joined the LSE on 27 March 2017. The Company
seeks to provide long-term shareholder returns, principally in the form of
sustainable income distributions from exposure to the life sciences industry.
The Company seeks to achieve this objective primarily through investments in
debt assets secured by royalties or other cash flows derived from the sales of
approved life sciences products.

 

 

 

LEI: 213800AV55PYXAS7SY24

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSSDFIUEISEDM